Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 4/20 | 0.48 |
| ▸ | MMP13 | P45452 | 1/20 | 0.38 |
| ▸ | REN | P00797 | 1/20 | 0.37 |
| ▸ | CTSL | P07711 | 1/20 | 0.36 |
| ▸ | CTSB | P07858 | 1/20 | 0.36 |
| ▸ | CTSS | P25774 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 1/20 | 0.36 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.34 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CPA1 | P15085 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL69223 | 1.00 | AAK1 (0.48) | AAK1MMP13RENCTSLCTSB | |
| SCHEMBL38056 | 1.00 | AAK1 (0.48) | AAK1MMP13RENCTSLCTSB | |
| Water SCHEMBL3825021 | 0.98 | AAK1 (0.47) | AAK1MMP13RENCTSLCTSB | |
| Ammonia Solution, Strong SCHEMBL28471283 | 0.98 | AAK1 (0.47) | AAK1MMP13RENCTSLCTSB | |
| Lactic Acid SCHEMBL27487871 | 0.95 | AAK1 (0.46) | AAK1MMP13RENCTSLCTSB | |
| SCHEMBL31191282 | 0.89 | AAK1 (0.40) | AAK1MMP13RENCTSLCTSB | |
| SCHEMBL31036506 | 0.89 | AAK1 (0.40) | AAK1MMP13RENCTSLCTSB | |
| SCHEMBL31522778 | 0.87 | AAK1 (0.41) | AAK1MMP13RENCTSLCTSB | |
| SCHEMBL30639575 | 0.86 | AAK1 (0.44) | AAK1MMP13RENCTSLCTSB | |
| SCHEMBL27032933 | 0.86 | AAK1 (0.44) | AAK1MMP13RENCTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 182 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103965299-B | A kind of ring pentapeptide and synthetic method thereof and application | 暨南大学 | 2016-07-13 | — | — | CN | claimed |
| CN-104861046-A | N-methyl cyclic pentapeptide compound and synthesis method and application thereof | UNIV HEBEI SCIENCE & TECH | 2015-08-26 | — | — | CN | claimed |
| CN-103965299-A | Cyclic pentapeptide as well as synthetic method and application thereof | UNIV JINAN | 2014-08-06 | — | — | CN | claimed |
| EP-4225762-B1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2026-05-27 | — | — | EP | disclosed |
| US-12612416-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2026-04-28 | — | — | US | disclosed |
| US-20260098060-A1 | MACROCYCLIC CFTR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2026-04-09 | — | — | US | disclosed |
| US-20260015313-A1 | AMINO ACID ACTIVE ESTER AND SALT THEREOF | PEPTIDREAM INC (JP) | 2026-01-15 | — | — | US | disclosed |
| EP-4534524-A1 | AMINO ACID ACTIVE ESTER AND SALT THEREOF | PeptiDream Inc. (JP) | 2025-04-09 | — | — | EP | disclosed |
| US-12240871-B2 | Method for producing peptide compound | NISSAN CHEMICAL CORPORATION (JP) | 2025-03-04 | — | — | US | disclosed |
| CN-118852175-A | Spiro compound crystal form and preparation method and application thereof | 深圳信立泰药业股份有限公司 | 2024-10-29 | — | — | CN | disclosed |
| US-12060333-B2 | Aminocarbamoyl compounds for the treatment of viral infections | HOFFMANN-LA ROCHE INC. (US) | 2024-08-13 | — | — | US | disclosed |
| US-5300492-A | Suppressing levels of sex hormones in male or female mammals | TAP PHARMACEUTICALS (US) | 1994-04-05 | — | — | US | disclosed |
| US-5110904-A | Luteinizing hormone releasing hormone; suppression of sex hormones | ABBOTT LABORATORIES (US) | 1992-05-05 | — | — | US | disclosed |
| EP-0400065-A4 | LHRH ANALOGS | — | 1991-03-13 | — | — | EP | disclosed |
| US-4997950-A | Antisecretory | MURPHY RICHARD FINBAR (US) | 1991-03-05 | — | — | US | disclosed |
| EP-0413209-A1 | LHRH analogs | TAP Pharmaceuticals Inc. (US) | 1991-02-20 | — | — | EP | disclosed |
| EP-0400065-A1 | LHRH ANALOGS. | ABBOTT LAB (US) | 1990-12-05 | — | — | EP | disclosed |
| CN-1039597-A | The antagonist of neurokinin A | MERRELL DOW PHARMA (US) | 1990-02-14 | — | — | CN | disclosed |
| WO-1989007450-A1 | LHRH ANALOGS | ABBOTT LABORATORIES (US) | 1989-08-24 | — | — | WO | disclosed |
| EP-0328090-A2 | LHRH analogs | ABBOTT LABORATORIES (US) | 1989-08-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260098060-A1 | MACROCYCLIC CFTR MODULATORS | CFTR, CLIC1, ARRB1 | AAK1 2966/4885MMP13 4473/4885REN 1062/4885 |
| US-20260015313-A1 | AMINO ACID ACTIVE ESTER AND SALT THEREOF | NSUN3, BCAT1, SLC43A1 | AAK1 4583/4885MMP13 2905/4885REN 503/4885 |
| US-12612416-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | CFTR, CLCN2, CLIC1 | AAK1 4659/4885MMP13 2194/4885REN 800/4885 |
| US-12240871-B2 | Method for producing peptide compound | NGLY1, NPPA, NPEPPS | AAK1 1920/4885MMP13 2428/4885REN 1579/4885 |
| US-12060333-B2 | Aminocarbamoyl compounds for the treatment of viral infections | SARS1, BCAT1, SLC1A5 | AAK1 3562/4885MMP13 3933/4885REN 88/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.